The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Josh Jennings - Cowen and Company - Analyst
: Hi, good morning. Thanks for taking the questions and congratulations on the strong sequential growth in Q2. I was hoping, Todd and Stephanie,
to just to ask about -- see if there's any incremental color you can provide. I mean, clearly, momentum was experienced in the second quarter, but
thinking about how you're doing more of that revenue guidance and what gets you there. Any help just thinking through the enterprise channel
and the successes you've had in 2Q? And any details you can provide on the sales front? I think you mentioned, Stephanie, about the strong pipeline.
But just what's giving you guys confidence in this reiteration of guidance and then the strong sequential growth that's implied in the back half of
2021?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 09, 2021 / 12:30PM, BFLY.N - Q2 2021 Butterfly Network Inc Earnings Call
Question: Josh Jennings - Cowen and Company - Analyst
: Great. Thank you for that. Wanted to ask about the heart failure study that you highlighted. Great proof of concept that patients can get track to
self-scan. But can you talk about the remaining steps of developing the home ultrasound scanning or heart failure opportunity? Any update on
the collaboration with the American College of Cardiology? And then maybe just help us understand better just the current level of utilization of
Butterfly in the home and how that's occurring currently?
Question: Josh Jennings - Cowen and Company - Analyst
: Excellent. Maybe one last question. Just thinking about the pipeline, Todd, and just how you see that evolving. And it's clear from your update
today that we're going to see a consistent flow of innovation and as you introduced today and updated today.
But how would you have investors think about the pipeline maybe into the out years and what we should be expecting in terms of the evolution
of the platform and advancements of imaging capabilities, image quality, and on the software side? Thanks for taking the questions.
Question: Josh Jennings - Cowen and Company - Analyst
: Thanks again. Appreciate it.
Question: Matt Taylor - UBS - Analyst
: Hey, thanks for taking the question. Can you hear me okay?
Question: Matt Taylor - UBS - Analyst
: Hey, good morning. So my first question was I wanted to ask you about the enterprise selling. How that's going? Maybe you could give us some
more specifics on your guide posts or things to look out for there? And what percentage of your sales do you expect to be in these kind of enterprise
agreements by the end of the year?
Question: Matt Taylor - UBS - Analyst
: Okay, great. And just a follow-up on the cadence of sales through the year. Could you talk about the kind of seasonality that we should expect?
And how back-end loaded do you expect the sales to be for the remainder of the year?
Question: Matt Taylor - UBS - Analyst
: Okay. Last one from my end. Just wanted to ask about the Canada approval and the OB/GYN applications. Maybe you could just comment on
whether we should view either of those as material commercially or how you expect those to ramp?
Question: Matt Taylor - UBS - Analyst
: Thank you.
| 
